Yaoxue Xuebao

Submission On

( Vol 60 , Issue 04 ) |

15 Sep 2025
Day
Hour
Min
Sec
Publish On

( Vol 60 , Issue 03 ) |

31 Aug 2025
Scopus Indexed (2025) scopus
ABCD Indexed (2025) scopus
scopus

Yaoxue Xuebao

Yaoxue Xuebao (ISSN:0513-4870) is a monthly peer-reviewed scopus-indexed journal from 1960, from 1962 to 1966, from 1979 to Present. The publisher of this journal is Chinese Pharmaceutical Association. Yaoxue Xuebao committed to gathering and disseminating excellent research achievements. The journal welcomes all kind of research/review/abstract papers regarding Pharmacology, Toxicology and Pharmaceutics, General Pharmacology and Toxicology and Pharmaceutics Biochemistry, Genetics and Molecular Biology and Molecular Medicine and so on.

Aim And Scope

Yaoxue Xuebao

Pharmacology

Toxicology and Pharmaceutics

General Pharmacology

Toxicology and Pharmaceutics Biochemistry

Genetics and Molecular Biology

Molecular Medicine

Latest Journal

Yaoxue Xuebao

  • YX-25-02-2025-2151
  • | Yaoxue Xuebao (ISSN:0513-4870)

Research progress on local anesthetic drug delivery systems based on covalent modification strategies

Local anesthetics (LAs) have been indispensable in clinical pain management, yet their limitations, such as short duration of action and systemic toxicity, necessitate improved delivery strategies. Hydrogels, with their biocompatibility, tunable properties, and ability to modulate drug release, have been extensively explored as platforms for enhancing LA efficacy and safety. This narrative review explores the historical development of LAs, their physicochemical properties, and clinical applications, providing a foundation for understanding the integration of hydrogels in anesthetic delivery

read more..
  • YX-25-02-2025-2150
  • | Yaoxue Xuebao (ISSN:0513-4870)

Study on multi-component contents of Jinqi Jiangtang Capsule

Natural deep eutectic solvents (NADESs), composed of natural primary metabolites, are now widely used as green and sustainable extraction solvents of bioactive components. In the present study, various NADESs were prepared to extract multi-components from different preparations of an herbal formula (Chinese name: Jinqi Jiangtang, JQJT) using ultrasound-assisted extraction (UAE). Results showed that most prepared NADESs provided more effective extraction of phenolic acids and alkaloids from JQJT preparations than conventional solvents. Among the tested NADESs, the solvent formed by choline c

read more..
  • YX-25-02-2025-2149
  • | Yaoxue Xuebao (ISSN:0513-4870)

Analysis of the proposal application and funding of National Natural Science Foundation of China in the field of synthetic medicinal chemistry in 2023

The discovery and advances of medicines may be considered as the ultimate relevant translational science effort that adds to human invulnerability and happiness. But advancing a fresh medication is a quite convoluted, costly, and protracted operation, normally costing USD ~2.6 billion and consuming a mean time span of 12 years. Methods to cut back expenditure and hasten new drug discovery have prompted an arduous and compelling brainstorming exercise in the pharmaceutical industry. The engagement of Artificial Intelligence (AI), including the deep-learning (DL) component in particular, has

read more..
  • YX-25-02-2025-2148
  • | Yaoxue Xuebao (ISSN:0513-4870)

Bifunctional molecules from viewpoint of medicinal chemistry

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as a result of the growing research interest in personalized medicine to improve diagnostic accuracy and intensify intensive therapy while limiting side effects. Radiometal-based drugs are of substantial interest because of their greater versatility for clinical translation compared to non-metal radionuclides. This paper comprehensively discusses various components commonly used as chemical scaffolds to build radiopharmaceutical agents, i.e., radionuclides, pharmacokinetic-modifying linkers, and chelators,

read more..
  • YX-25-02-2025-2147
  • | Yaoxue Xuebao (ISSN:0513-4870)

Advances of antibody drug conjugates in pancreatic cancer therapy

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry o

read more..

The publisher of this journal is Chinese Pharmaceutical Association. Yaoxue Xuebao committed to gathering and disseminating excellent research achievements.

Information
Guidelines
Contact Us
  • journalpublication435@gmail.com
  • admin@yaoxuexuebao-05134870.com
  • support@yaoxuexuebao-05134870.com
All rights reserved | © 2024 Yaoxue Xuebao (ISSN:0513-4870).